Table 2 Demographic data
Indication | Study, reference | Treatment | Age (years) mean ± SD, range | Sex | |
|---|---|---|---|---|---|
Female | Male | ||||
Acute tonsillopharyngitis | A Timen et al., 2015 [60] | EPs 7630 (n = 40) | 7.4 ± 1.2, 6–9 | 26 (65.0%) | 14 (35.0%) |
Placebo (n = 38) | 7.7 ± 1.2, 6–9 | 18 (47.4%) | 20 (52.6%) | ||
B Berezhnoi et al., 2016 [55] | EPs 7630 (n = 60) | 7.6 ± 1.1, 6–9 | 29 (48.3%) | 31 (51.7%) | |
Placebo (n = 64) | 7.4 ± 1.2, 6–9 | 28 (43.8%) | 36 (56.3%) | ||
C Bereznoy et al., 2003 [56] | EPs 7630 (n = 73) | 7.6 ± 1.3, 6–9 | 40 (54.8%) | 33 (45.2%) | |
Placebo (n = 70) | 7.5 ± 1.1, 6–9 | 30 (42.9%) | 40 (57.1%) | ||
Acute bronchitis | D§ Kamin et al., 2010a [58] | EPs 7630 (n = 25) | 7.8 ± 1.3, 6–10 | 14 (56.0%) | 11 (44.0%) |
Placebo (n = 24) | 7.9 ± 1.7, 6–10 | 11 (45.8%) | 13 (54.2%) | ||
E§ Kamin et al., 2010b [59] | EPs 7630 (n = 32) | 8.2 ± 1.3, 6–10 | 16 (50.0%) | 16 (50.0%) | |
Placebo (n = 31) | 7.9 ± 1.5, 6–10 | 15 (48.4%) | 16 (51.6%) | ||
F§ Kamin et al., 2012 [57] | EPs 7630& (n = 35) | 7.7 ± 1.3, 6–10 | 21 (60.0%) | 14 (40.0%) | |
Placebo (n = 31) | 7.4 ± 1.3, 6–10 | 16 (51.6%) | 15 (48.4%) | ||
Pooled data (acute tonsillopharyngitis + acute bronchitis) | EPs 7630 (n = 265) | 7.7 ± 1.2, 6–10 | 146 (55.1%) | 119 (44.9%) | |
Placebo (n = 258) | 7.6 ± 1.3, 6–10 | 118 (45.7%) | 140 (54.3%) | ||